Abstract
Abstract only
- Title
- Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study
- Creators
- Bradley J. Monk - Creighton UniversityAndres Poveda - Fundación Instituto Valenciano de OncologíaIgnace Vergote - KU LeuvenFrancesco Raspagliesi - Fondazione IRCCS Istituto Nazionale dei TumoriKeiichi Fujiwara - Saitama Medical UniversityDuk-Soo Bae - Samsung Medical CenterAna Oaknin - Vall d'Hebron Institute of Oncology, Barcelona, SpainIsabelle Ray-Coquard - Centre Léon BérardDiane M. Provencher - Centre Hospitalier de l’Université de MontréalBeth Y. Karlan - Cedars-Sinai Medical CenterCatherine Lhommé - Institut Gustave RoussyGary Richardson - Cabrini HospitalDolores Gallardo Rincon - Subdirección de Medicina Interna, Instituto Nacional de Cancerologia, Mexico City, MexicoRobert L. Coleman - The University of Texas MD Anderson Cancer CenterArija Brize - Latvian Oncology Center, Riga Eastern Clinical University Hospital, Riga, LatviaKathy Zhang - AmgenFlorian D. Vogl - AmgenBruce A. Bach - AmgenAmit M. Oza - Princess Margaret Cancer Centre
- Publication Details
- Journal of clinical oncology, Vol.33(15_suppl), pp.5503-5503
- Identifiers
- 991005969014102656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article